Monday February 26, 2018

Delhi records 3,829 cases of dengue, 502 of chikungunya till date

The year 2015 had reported the highest number of cases of dengue in the city, with the figure standing at 15,867 with 60 deaths.

0
//
31
cases of dengue
Dengue and Chikungunya are viral diseases transmitted to humans via infected mosquitoes. Pixabay
Republish
Reprint

New Delhi, November 7, 2017 :  Delhi has so far recorded 3,829 cases of dengue and 502 cases of chikungunya, according to civic agencies on Monday.

While the national capital has witnessed a total of four dengue-related deaths till now, no deaths have been reported due to chikungunya.

ALSO READ You May Soon Be Able to Prevent Chikungunya With Vaccines! IIT-Roorkee Researchers Discover Drug to Fight the Disease

The year 2015 reported the highest number of cases of dengue in the city, with the figure standing at 15,867 with 60 deaths.

As for chikungunya, 2016 saw 7,117 cases — the highest in the last five years.

Civic agencies said that areas under the South Delhi Municipal Corporation reported the maximum cases of chikungunya and dengue this year.

ALSO READ What preventive steps have the city Government taken to control Dengue and Chikungunya, asks the Delhi High Court

Delhi has also reported a total of 552 malaria cases with no deaths so far. The figure is the second-highest after 2012 when the cases had soared to 822. (IANS)

Click here for reuse options!
Copyright 2017 NewsGram

Next Story

You May Soon Be Able to Prevent Chikungunya With Vaccines! IIT-Roorkee Researchers Discover Drug to Fight the Disease

At present, there are no immunizations or anti-viral medications available to cure Chikungunya, and the treatment is focused on mitigating the side effects related with the disease

0
//
78
cases of dengue
Dengue and Chikungunya are viral diseases transmitted to humans via infected mosquitoes. Pixabay

Roorkee, October 9, 2017 : Dengue and Chikungunya are known to strike fear in the country every year, so much so that the health graph of the city registers a steep rise in these cases. Both of the water-borne diseases, characterized by high fever and pain in the joints, take a toll on our lives. So far, there is no vaccine to immunize people against the spread of the Dengue and Chikungunya virus. However, researchers at IIT-Roorkee have now discovered that a commonly-utilized de-worming drug can be efficiently used for treatments against Chikungunya.

According to a report by PTI, Shailly Tomar, lead researcher and a professor at Indian Institute of Technology (IIT) Roorkee in Uttarakhand was quoted as saying, “Our research has shown that piperazine, a drug existing in the market, is successful in curbing the spread and replication of the Chikungunya virus in a lab setting.”

The drug, Piperazine, is usually used in de-worming treatments against round-words and pinworms. Using their expertise in virology and structure biology, experts have now discovered the anti-viral capabilities of the drug that can potentially prompt new therapies against the fatal, mosquito borne disease.

The researchers are currently testing the molecule on animals, and will consequently take it to clinical trials.

ALSO READ What preventive steps have the city Government taken to control Dengue and Chikungunya, asks the Delhi High Court

The molecular details uncovered in the study, which has been published in the journal Antiviral Research, will be additionally used to plan piperazine-derivative medications that are more compelling to fight against the Chikungunya virus.

Using X-ray crystallographic technique, in combination with computational science and fluorescence strategies, the researchers discovered that piperazine binds itself with the hydrophobic (water-hating) pocket of capsid protein present in the Chikungunya virus, which can reduce the spread of the virus.

“This pocket is key to the replication of the virus and its spread inside a host. Inhibiting the pocket prevents budding and spread of the virus and can help in treating the virus effectively using existing drugs,” Tomar said.

Chikungunya has become a major public health concern, with an increasing number of people being plagued by the disease every year.

 At present, there are no immunizations or anti-viral medications available to cure Chikungunya, and the treatment is focused on mitigating the side effects related with the disease. 

Developing a new anti-viral drug molecule can take up to 10 years. To tend to the disease on an immediate basis, Professor Tomar added, “We are looking at repositioning existing, approved drugs and testing these to see if they might inhibit or kill pathogenic viruses.”

 

 

Next Story